Notice2023-03846
National Institute on Drug Abuse; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 24, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 37 (Friday, February 24, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 37 (Friday, February 24, 2023)]
[Notices]
[Pages 11926-11927]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-03846]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
[[Page 11927]]
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Mechanism for Time-Sensitive Drug Abuse Research.
Date: March 20, 2023.
Time: 12:00 p.m. to 1:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D.,
Scientific Review Officer, Scientific Review Branch, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
Bethesda, MD 20892, (301) 443-4577, <a href="/cdn-cgi/l/email-protection#e59690818d8c978e90888497cb9c848b9584898980928497a58b8c8dcb828a93"><span class="__cf_email__" data-cfemail="d1a2a4b5b9b8a3baa4bcb0a3ffa8b0bfa1b0bdbdb4a6b0a391bfb8b9ffb6bea7">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEAL Initiative: HEAL Data2Action--Innovation and
Acceleration Projects, Phased Awards.
Date: March 22, 2023.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
Bethesda, MD 20892, (301) 827-5843 <a href="/cdn-cgi/l/email-protection#611513080f094f1513000f210f08094f060e17"><span class="__cf_email__" data-cfemail="96e2e4fff8feb8e2e4f7f8d6f8fffeb8f1f9e0">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Registry of Medical Cannabis Use and Health
Outcomes.
Date: March 24, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, Bethesda, MD
20892, (301) 827-5819, <a href="/cdn-cgi/l/email-protection#89eee4b8bdbce8c9e7e0e1a7eee6ff"><span class="__cf_email__" data-cfemail="593e34686d6c3819373031773e362f">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Omnibus Topic 167: Cause of Death Elucidated (CODE)
in Drug Overdose: Research and Development of New Postmortem
Toxicology Screening Devices That Are Portable, Rapid, Accurate,
Affordable, and Accessible.
Date: March 30, 2023.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, Bethesda, MD
20892, (301) 827-5819, <a href="/cdn-cgi/l/email-protection#9dfaf0aca9a8fcddf3f4f5b3faf2eb"><span class="__cf_email__" data-cfemail="33545e02070652735d5a5b1d545c45">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: February 17, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-03846 Filed 2-23-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 24, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.